Tech Company Financing Transactions

Psyadon Pharmaceuticals Funding Round

Psyadon Pharmaceuticals, operating out of Germantown, secured $2 million from New Enterprise Associates.

Transaction Overview

Announced On
12/31/2010
Transaction Type
Venture Equity
Amount
$2,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
20451 Seneca Meadows Parkway
Germantown, MD 20876
USA
Email Address
Overview
Psyadon Pharmaceuticals is dedicated to the discovery and development of new treatments for the serious psychiatric and neurological diseases. Ecopipam, our first development candidate, selectively blocks the actions of the neurotransmitter dopamine at the D1 subtype in the brain.
Profile
Psyadon Pharmaceuticals LinkedIn Company Profile
Social Media
Psyadon Pharmaceuticals Company Twitter Account
Company News
Psyadon Pharmaceuticals News
Facebook
Psyadon Pharmaceuticals on Facebook
YouTube
Psyadon Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Richard Chipkin
  Richard Chipkin LinkedIn Profile  Richard Chipkin Twitter Account  Richard Chipkin News  Richard Chipkin on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/31/2010: Aveso Displays venture capital transaction
Next: 12/31/2010: Ingrain venture capital transaction

 

Share this article

 


About Our VC Transactions Data

Our team works diligently to report on funding rounds that are announced publicly. All VC database entries reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary